Key Documents

View All Documentation

SML0148

Imidapril hydrochloride

Name: Imidapril hydrochloride
Brand: SIGMA

≥98% (HPLC)

Synonym(s):

(4S)-3-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-4-imidazolidinecarboxylic acid hydrochloride, Novaloc, TA 6366, Tanapril

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₂₀H₂₇N₃O₆ · HCl

CAS Number:

89396-94-1

Molecular Weight:

441.91

NACRES:

NA.77

PubChem Substance ID:

329825196

UNSPSC Code:

12352200

MDL number:

MFCD00923828

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

Quality Level

100

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -50 to -70° in ethanol (c=0.5)

color

white to tan

solubility

H₂O: ≥5 mg/mL

originator

Trinity Pharma Solutions

storage temp.

−20°C

SMILES string

Cl.CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2[C@@H](CN(C)C2=O)C(O)=O

InChI

1S/C20H27N3O6.ClH/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28;/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26);1H/t13-,15-,16-;/m0./s1

InChI key

LSLQGMMMRMDXHN-GEUPQXMHSA-N

Description

General description

Imidapril comprises large acyl moiety and is hydrolyzed by carboxylesterase (CES) 1.

Application

Imidapril hydrochloride may be used to test its effect on pharyngeal and laryngeal muscle to treat impaired swallowing.

Imidapril hydrochloride was used as a standard in bioequivalence test by LC/MS method.

Biochem/physiol Actions

Angiotensin Converting Enzyme (ACE) inhibitor

Imidapril hydrochloride is a long-acting inhibitor of angiotensin converting enzyme used in the treatment of hypertension, congestive heart failure and diabetic nephropathy. It restores decreased airway sensation and bladder sensation in patients with multiple sclerosis.

Imidapril is a potent angiotensin converting enzyme inhibitor and anti-hypertensive.

Features and Benefits

This compound is featured on the Angiotensin Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Trinity Pharma Solutions. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

015M4706V

101M4715V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

Angiotensin Receptors

We offer many products related to angiotensin receptors for your research needs.

Beneficial effects of a combination of Rho-kinase inhibitor and ACE inhibitor on tubulointerstitial fibrosis induced by unilateral ureteral obstruction.

Yosuke Takeda et al.

Hypertension research : official journal of the Japanese Society of Hypertension, 33(9), 965-973 (2010-07-29)

We and others recently reported that long-term Rho-kinase inhibition has renoprotective effects. This study was designed to compare the effects of an angiotensin-converting enzyme (ACE) inhibitor (imidapril), a Rho-kinase inhibitor (fasudil) and a combination of them both on renal interstitial

Angiotensin-converting enzyme inhibition augments coronary release of tissue plasminogen activator in women but not in men.

Tetsuya Matsumoto et al.

Hypertension (Dallas, Tex. : 1979), 56(3), 364-368 (2010-07-08)

The renin-angiotensin system regulates the vascular fibrinolytic balance. In the human forearm vasculature, angiotensin-converting enzyme (ACE) inhibitors (ACE-Is) increase the release of t-PA through endogenous bradykinin. We tested the hypothesis that ACE inhibition and sex modulate the endogenous coronary release

Addition of losartan to angiotensin-converting enzyme inhibitors improves insulin resistance in patients with chronic heart failure treated without β-blockers.

Kazuhide Ogino et al.

Circulation journal : official journal of the Japanese Circulation Society, 74(11), 2346-2352 (2010-09-10)

Angiotensin II and insulin resistance (IR) have clinical implications in the pathophysiology of chronic heart failure (CHF). However, it is still unclear whether the combination of an angiotensin-receptor blocker and angiotensin-converting enzyme inhibitor (ACEI) improves IR in CHF patients who

View All Related Papers

Global Trade Item Number

SKU	GTIN
SML0148-10MG	04061833221938
SML0148-50MG	04061833221945

Key Documents

Imidapril hydrochloride

≥98% (HPLC)

Select a Size

About This Item

Quality Level

assay

form

optical activity

color

solubility

originator

storage temp.

SMILES string

InChI

InChI key

General description

Application

Biochem/physiol Actions

Features and Benefits

Safety Information

Storage Class

wgk

flash_point_f

flash_point_c

Regulatory Information

Documentation

Certificates of Analysis (COA)

Already Own This Product?

Protocols and Articles

Articles

Peer Reviewed Papers

Global Trade Item Number